To ask His Majesty's Government what assessment they have made of long-term and permanent harm caused by the use of benzodiazepines, Z-drugs and antidepressants.

To ask His Majesty's Government what assessment they have made of long-term and permanent harm caused by the use of benzodiazepines, Z-drugs and antidepressants.

To ask the Secretary of State for Health and Social Care, if he will make an estimate of the number of people that have been prescribed sleeping pills in the last five years.

To ask the Secretary of State for Health and Social Care, if he will make an estimate of the number of people that have been prescribed sleeping pills in the last five years.

To ask the Secretary of State for Health, how many prescriptions for sleeping tablets were dispensed in (a) Liverpool, Wavertree constituency, (b) Liverpool and (c) each region in each month of each year since 2010.

To ask the Secretary of State for Health, how many prescriptions for sleeping tablets were dispensed in (a) Liverpool, Wavertree constituency, (b) Liverpool and (c) each region in each month of each year since 2010.

To ask the Secretary of State for Health, what recent representations he has received on the prescription of zolpidem.

To ask the Secretary of State for Health, what recent representations he has received on the prescription of zolpidem.

To ask the Secretary of State for Health (1) how many prescriptions for sleeping tablets were dispensed to people aged (a) under 18, (b) between 18 and 25, (c) between 50 and 64 and (d) over 64 years in each of the last five years;

To ask the Secretary of State for Health (1) how many prescriptions for sleeping tablets were dispensed to people aged (a) under 18, (b) between 18 and 25, (c) between 50 and 64 and (d) over 64 years in each of the last five years;

(2) how many prescriptions for sleeping tablets were dispensed in each of the last five years.

(2) how many prescriptions for sleeping tablets were dispensed in each of the last five years.

To ask the Secretary of State for Health what the (a) total number of and (b) net ingredient cost of drugs dispensed in the community for the treatment of insomnia was in each year since 1997.

To ask the Secretary of State for Health what the (a) total number of and (b) net ingredient cost of drugs dispensed in the community for the treatment of insomnia was in each year since 1997.

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What restrictions are in place on advertising drugs available without prescription which are designed to aid sleep; what checks are carried out to ensure that addictive or potentially harmful drugs are not advertised for mass consumption; what health warnings should be given in such advertisements; in what ways regulations or...

What advice he has recently received from his Advisory Council on the Misuse of Drugs concerning hypnotics; what conclusions he has reached in the light of any such advice.

What advice he has recently received from his Advisory Council on the Misuse of Drugs concerning hypnotics; what conclusions he has reached in the light of any such advice.

If she will publish her correspondence with the Chairman of the Medicines Commission regarding the decision of the Licensing Authority to revoke all licences for triazolam products. - There has been no such correspondence.

If she will publish her correspondence with the Chairman of the Medicines Commission regarding the decision of the Licensing Authority to revoke all licences for triazolam products. - There has been no such correspondence.

What representations she has received from the Panel of Persons Appointed since announcing the revocation of all licences for triazolam products on 9th June. - None.

What representations she has received from the Panel of Persons Appointed since announcing the revocation of all licences for triazolam products on 9th June. - None.

If she will publish her correspondence with the Chairman of the Panel of Persons Appointed regarding the decision of the Licensing Authority to revoke all licences for triazolam products. - Includes ref to note on the licensing authority's position on triazolam in Library (DEP 9336).

If she will publish her correspondence with the Chairman of the Panel of Persons Appointed regarding the decision of the Licensing Authority to revoke all licences for triazolam products. - Includes ref to note on the licensing authority's position on triazolam in Library (DEP 9336).

What conclusions she has drawn regarding the implications of the revocation of licences for triazolan products for the future of the appeals procedure set out in the Medicines Act 1968.

What conclusions she has drawn regarding the implications of the revocation of licences for triazolan products for the future of the appeals procedure set out in the Medicines Act 1968.

What was the number of adverse drug reaction reports through the yellow card system for each year from 1978 to 1991 for Triazolam; and how many of these were categorised as serious. - Inc table.

What was the number of adverse drug reaction reports through the yellow card system for each year from 1978 to 1991 for Triazolam; and how many of these were categorised as serious. - Inc table.

If he will sub-peona Professor Ian Oswald, Emeritus Professor of Psychiatry in the University of Edinburgh, in relation to clinical trials, relating to the sleeping pill, triazolam, known as Halcion. - Will write. (Holding answer 17 October 1991).

If he will sub-peona Professor Ian Oswald, Emeritus Professor of Psychiatry in the University of Edinburgh, in relation to clinical trials, relating to the sleeping pill, triazolam, known as Halcion. - Will write. (Holding answer 17 October 1991).

If he will make it his policy to tighten monitoring procedures on psychotropic drugs, in the light of the withdrawal of triazolam; to establish an inquiry into the conduct of the Committee on Safety of Medicines with respect to triazolam; to undertake a study into the safety of the other...

If he will make it his policy to tighten monitoring procedures on psychotropic drugs, in the light of the withdrawal of triazolam; to establish an inquiry into the conduct of the Committee on Safety of Medicines with respect to triazolam; to undertake a study into the safety of the other...